Dr Jasjit Baveja is the Associate Director of Policy at the Medical Technology Association of Australia (MTAA), where she oversees regulatory affairs, clinical code of practice, procurement, industry policy, reimbursement, and advocacy. With over 20 years of experience in the medical device regulatory space, Dr Bavej’s expertise lies in providing educational opportunities for regulatory professionals in Australia to ensure continuous learning and professional development. She collaborates closely with the Therapeutic Goods Administration (TGA) to run workshops that provide invaluable experience, networking opportunities, and skill enhancement.
Regulations, such as the Therapeutic Goods Act of 1989, the Therapeutic Goods Regulations of 1990, and the Therapeutic Goods Medical Device Regulations of 2002, serve as a cornerstone for the medical technology industry and are essential in ensuring patient safety and promoting innovation within the industry.
According to Dr Baveja, “Setting stringent quality standards throughout the lifecycle of the medical device, regulations safeguard patient and public health by ensuring only safe and effective medical devices are on the market. With the confidence instilled in patients, healthcare workers, and broader stakeholders that any device that has gone through rigorous testing has met the scrutiny of regulatory requirements, the uptake of medical technology and novel medical devices is facilitated.”
MTAA offers workshops in medical device regulatory affairs for regulatory professionals, providing comprehensive education on Australian medical device regulations to enhance patient access to medical devices and streamline regulatory processes for faster approval times.
The Medical Technology Association of Australia (MTAA) is the national association representing companies in the medical technology industry.
MTAA represents manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and management of disease and disability. The range of medical technology is diverse with products ranging from familiar items such as syringes and wound dressings, through to high-technology implanted devices such as pacemakers, defibrillators, hip and other orthopaedic implants. Products also include hospital and diagnostic imaging equipment such as ultrasounds and magnetic resonance imaging machines.
-
Michelle Fenwick – Northern Health
The outskirts of Melbourne is experiencing significant population growth over the next 10 years and Northern Health has taken preemptive steps to ensure the supply of new talented healthcare staff as well as develop the culture of the workplace.
Michelle Fenwick, the Executive Director of Northern Health spoke with our reporter Anne Dao on the challenges of this urban growth over the past 3 years. By 2031 the region is expected to increase in population by 63%. Added to this is hiring and training the right workforce to align with the clinical care needs of people coming into the healthcare centres.
Culture is forming in a growing organisation with approximately 70% of staff having been at Northern Health less than 4 years. However there is opportunity for clinical staff to accelerate their career in such an environment
-
Concerning increases in Non-Alcoholic Fatty Liver Disease and colorectal cancer
Dr Kieran Longley is a Gastroenterologist and Hepatologist committed to providing comprehensive, patient-centred care across a broad spectrum of digestive and liver conditions. He completed his medical degree at the University of Tasmania before undertaking physician training at St Vincent’s Hospital Sydney. Furthering his academic and clinical expertise, he obtained a Master of Science in Internal Medicine from the University of Edinburgh.
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
